AbCellera rises as FDA approves Jazz Ziihera regimens
AbCellera Biologics shares trade higher on Tuesday as investors react to FDA approval of Jazz Pharmaceuticals’ two Ziihera-containing first-line regimens, with no company-specific catalyst supplied.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.